تحسين النتائح
ترتيب حسب
من
الى
الصفحة 1
الصفحة 1
Mass Vaccination : Global Aspects - Progress and Obstacles
Mass immunization is the blitzkrieg of vaccination practice. It serves to rapidly protect populations, both because of the high coverage achieved and because of the herd immunity thereby induced. However, as in war, mass immunization campaigns must be conducted intelligently, with careful strategy and strong attention to logistics of supply and deployment. If conducted badly, mass immunization may fail or even be counter-productive. In this volume, some of the most successful practitioners of mass im- nization tell us about its art and science. David Heymann and Bruce Aylward of WHO begin the book with a theoretical and practical overview of mass immunization. Michael Lane, who participated in the successful effort to eradicate smallpox relates how this was done using mass vaccination and other strategies. Application of mass immunization by the US military is c- ered by John Grabenstein and Remington Nevin, who have a large experience in these matters. Karen Noakes and David Salisbury recount the striking s- cesses of mass immunization in the United Kingdom. The global control of the clostridia that produce diphtheria toxin is described by Charles Vitek. Hepa- tis A is decreasing dramatically under the impact of large-scale vaccination, as Francis André illustrates. The French experience with Hepatitis B vac- nation has been mixed, and François Denis and Daniel Levy-Bruhl explain the circumstances. In?uenza vaccination is an annual example of large-scale campaigns, the complexity of which is recounted by Benjamin Schwartz and Pascale Wortley.
Liver Immunology : Principles and Practice
parasitic and viral infections of the liver, autoimmune liver disease, alcoholic and nonalcoholic fatty liver diseases, and transplantation in an easy-to-read and thorough format. Authors also address the key issues that have arisen in this field in recent years, including physiological roles of hepatocytes, sinusoidal lining cells, activated macrophages (Kupffer cells), cholangiocytes and stellate cells, and their modulation of T cells, natural killer (NK) cells and NKT cells.
Comparative Hepatitis
This volume reviews today’s knowledge about hepatitis with emphasis on comparative aspects between hepatitis in humans and animals, but also between different etiological agents. This particular viewpoint makes the book relevant for scientists from both human and veterinary medicine, gastroenterologists, pathologists, virologists and students of human and veterinary medicine.
Clinical microbiology made ridiculously simple
Is a brief, clear, thorough, and updated approach to clinical microbiology, brimming with mnemonics, humor, summary charts, and illustrations. Topics include Ebola, AIDS, flesh-eating bacteria, mad cow disease, hantavirus, anthrax, smallpox, and tuberculosis; the latest antibiotics; pandemic flu, including H7N9; SARS-like coronavirus; hepatitis C treatment options; HIV diagnostics and approved HIV meds; Zika virus; measles; and a new chapter on the latest emerging infectious diseases and drug-resistant bacteria. The major update to this book is the addition of a new chapter on the SARS-COV-2 virus and COVID-19 disease, which delves into the nature of the virus such as infectivity within the body, transmission between individuals, timeline of infectivity, symptoms, risk factors, therapeutics, and vaccines approved for use.
Cholestatic Liver Disease
Cholestatic Liver Disease provides essential information for individuals involved in the care of patients affected by cholestatic liver disease. This groundbreaking text also supplies scientific updates from leading experts which relate to the clinical evaluation and management of cholestatic liver disorders, useful for both novice and practitioners alike.
Cancer drug safety and public health policy : A changing landscape
Description and analysis of recent developments and current trends in health policy with regard to cancer drug safety. Opens with an overview of pharmacovigilance for cancer blockbuster drugs, covering both general considerations and efforts to develop a structured framework for the identification and reporting of adverse drug reactions (ADRs). A number of important examples of serious ADRs to hematology and oncology drugs are then reviewed, with evaluation of the lessons learned and the policy implications of the ensuing legal cases and their settlements. Further, the difficulty of reporting such blockbuster side effects in the medical literature is explored in an empirical study. Significant advances have been achieved in analytic methods for the identification of ADRs, and here there is a particular focus on the value of optimal discriminant analysis. Finally, the impacts on pharmacovigilance and drug safety of the huge fines paid under the U.S. False Claims Act relating to the defrauding of governmental programs also receive careful attention – these fines are playing an important role in changing the landscape for pharmaceutical safety.
